Prostate cancer prevention trials in the USA

被引:51
作者
Brawley, OW
Parnes, H
机构
[1] Natl Canc Inst, Bethesda, MD 20852 USA
[2] NCI, Div Canc Prevent, Bethesda, MD 20852 USA
关键词
prostate; prostate cancer; chemoprevention; clinical trials; 5-alpha-reductase inhibitor; selenium; alpha tocopherol;
D O I
10.1016/S0959-8049(00)00105-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There is dramatic international variation in prostate cancer mortality rates. The variation suggests that the disease has an environmental cause and encourages the search for a way to prevent it. Androgenic stimulation over a period of time, perhaps due to a high fat diet, has been suggested as a cause of prostate cancer. The corollary to this hypothesis is that lowering androgenic stimulation over time will prevent prostate cancer. 5-Alpha-reductase inhibition through drugs like finasteride have been shown to decrease androgenic stimulation or the prostate. A clinical trial is underway using finasteride to assess this hypothesis. Epidemiological and laboratory studies also suggest that those with high selenium and vitamin E intake have a lower risk of prostate cancer. Recent serendipitous findings of two randomised clinical trials support this. A study to assess these compounds is currently being designed. Other promising but less developed interventions in the chemoprevention of prostate cancer include vitamin D supplementation and diet modification. (C) 2000 Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1312 / 1315
页数:4
相关论文
共 33 条
[1]   alpha-tocopherol and beta-carotene supplements and lung cancer incidence in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study: Effects of base-line characteristics and study compliance [J].
Albanes, D ;
Heinonen, OP ;
Taylor, PR ;
Virtamo, J ;
Edwards, BK ;
Rautalahti, M ;
Hartman, AM ;
Palmgren, J ;
Freedman, LS ;
Haapakoski, J ;
Barrett, MJ ;
Pietinen, P ;
Malila, N ;
Tala, E ;
Liippo, K ;
Salomaa, ER ;
Tangrea, JA ;
Teppo, L ;
Askin, FB ;
Taskinen, E ;
Erozan, Y ;
Greenwald, P ;
Huttunen, JK .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (21) :1560-1570
[2]  
[Anonymous], 1994, Ann Epidemiol, V4, P1, DOI 10.1016/1047-2797(94)90036-1
[3]   FINASTERIDE DOSE-DEPENDENCY REDUCES THE PROLIFERATION RATE OF THE LNCAP HUMAN PROSTATIC-CANCER CELL-LINE IN-VITRO [J].
BOLOGNA, M ;
MUZI, P ;
BIORDI, L ;
FESTUCCIA, C ;
VICENTINI, C .
UROLOGY, 1995, 45 (02) :282-290
[4]  
BRAWLEY OW, 1994, CANCER EPIDEM BIOMAR, V3, P177
[5]   What causes prostate cancer? A brief summary of the epidemiology [J].
Chan, JM ;
Stampfer, MJ ;
Giovannucci, EL .
SEMINARS IN CANCER BIOLOGY, 1998, 8 (04) :263-273
[6]  
Clark LC, 1998, BRIT J UROL, V81, P730
[7]  
Coltman CA, 1999, EUR UROL, V35, P544
[8]   INHIBITION OF THE ACTIVITY OF BASIC 5-ALPHA-REDUCTASE (TYPE-1) DETECTED IN DU 145 CELLS AND EXPRESSED IN INSECT CELLS [J].
DELOS, S ;
IEHLE, C ;
MARTIN, PM ;
RAYNAUD, JP .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1994, 48 (04) :347-352
[9]   Finasteride in the treatment of benign prostatic hypertrophy: an update - New indications for Finasteride therapy [J].
Ekman, P .
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 1999, 33 :15-20
[10]   DESIGN OF THE PROSTATE-CANCER PREVENTION TRIAL (PCPT) [J].
FEIGL, P ;
BLUMENSTEIN, B ;
THOMPSON, I ;
CROWLEY, J ;
WOLF, M ;
KRAMER, BS ;
COLTMAN, CA ;
BRAWLEY, OW ;
FORD, LG .
CONTROLLED CLINICAL TRIALS, 1995, 16 (03) :150-163